AZD3409
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Farnesyltransferase inhibitors (FTIs) have mainly been used in cancer therapy. However, more recently, investigations on these…
The kinetics of the HCl-catalyzed deprotection of the Boc-protected amine, thioester 2 to liberate AZD3409 1 have been studied in…
PurposeAZD3409 is a novel DPTI that has potent activity against both FTase and GGTase-1. The in vitro inhibition profile of…
The aim of the present investigation is to develop a simple, fast, and sensitive method for the determination of a new candidate…
AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the…
AKT and MAPK signaling are involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. RAS…
Mutations at the H-, N-, and K-ras loci are among the most frequent genetic alterations in human cancers. In this study, we have…
The therapeutic utility of trastuzumab ('Herceptin') in breast cancer patients with tumours that overexpress erbB2 established…
4744 Background: Prostate cancer is the most common malignancy in men with a predilection to metastasize to the bone. There is a…
3172 Background: AZD3409 is a novel, oral, antitumor agent that acts as a prenyl transferase inhibitor. It has potentially broad…